SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
AN2 Therapeutics, Inc. (ANTX) has a negative trailing P/E of -2.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -35.49%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+160.1%).
- Trailing Earnings Yield -35.49% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $7.75 (+160.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ANTX
Valuation Multiples
P/E (TTM)-2.8
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio1.87
P/S Ratio0.00
EV/EBITDA-1.8
Per Share Data
EPS (TTM)$-1.16
Book Value / Share$1.76
Revenue / Share$0.00
FCF / Share$-0.99
Yields & Fair Value
Earnings Yield-35.49%
Dividend Yield0.00%
Analyst Target$7.75 (+160.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-8.5 |
0.00 |
59.96 |
0.00 |
- |
| 2020 |
-21.2 |
-0.13 |
104.91 |
0.00 |
- |
| 2021 |
-13.4 |
-0.15 |
4.66 |
0.00 |
- |
| 2022 |
-3.6 |
-0.04 |
1.53 |
0.00 |
- |
| 2023 |
-7.5 |
4.17 |
3.88 |
0.00 |
- |
| 2024 |
-0.8 |
0.02 |
0.50 |
0.00 |
- |
| 2025 |
-1.0 |
0.03 |
0.65 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.30 |
$0.00 |
$-5.64M |
- |
| 2020 |
$-0.97 |
$0.00 |
$-13.6M |
- |
| 2021 |
$-1.55 |
$0.00 |
$-21.54M |
- |
| 2022 |
$-2.79 |
$0.00 |
$-40.96M |
- |
| 2023 |
$-2.74 |
$0.00 |
$-64.73M |
- |
| 2024 |
$-1.72 |
$0.00 |
$-51.32M |
- |
| 2025 |
$-1.16 |
$0.00 |
$-35.17M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.91 |
$-0.91 – $-0.91 |
$72.7M |
$72.7M – $72.7M |
1 |
| 2027 |
$-0.80 |
$-0.80 – $-0.80 |
$217M |
$217M – $217M |
1 |
| 2028 |
$-1.02 |
$-1.02 – $-1.02 |
$389.9M |
$389.9M – $389.9M |
1 |
